1. Introduction {#s0005}
===============

Lynch syndrome (LS) is an autosomal dominant tumor predisposition condition caused by mutations in the mismatch repair (MMR) genes. The syndrome was first described in 1913 by Warthin and further delineated by Lynch in 1966 [@bb0005]. Lynch syndrome is thought to affect 1:2000 to 1:370 individuals [@bb0010], [@bb0015]. As a result of a dysfunctional MMR system, cells become hyper-mutated with a high microsatellite (MSI-H) instability phenotype; mutations in the oncoprotective genes eventually lead to neoplastic changes and tumorigenesis. Mutation carriers are at high risk of colorectal cancer (CRC), endometrial cancer (EC) and a spectrum of other malignancies, including ovarian cancer (OC). Diagnosis is suspected from clinical presentation and family history, and confirmed with immunohistochemistry, MSI analysis and ultimately genomic sequencing of the known MMR genes.

OC is the leading cause of death from gynecological cancer in the developed world [@bb0020]. Symptoms are often vague at onset leading to a delayed diagnosis. The lifetime risk of Lynch syndrome-associated OC (LSAOC) is in the region of 6--14% [@bb0020], [@bb0025], with around 2% of all ovarian cancers due to Lynch syndrome, although studies are lacking and sample sizes are small [@bb0030]. There is a clinical imperative to identify LSAOC since surveillance strategies can be used to identify and treat premalignant and early stage cancers of other anatomical sites, particularly those of the rectum and colon. In addition, potentially affected relatives can be offered diagnostic testing. Lynch syndrome-associated colorectal cancers have distinctive pathological features that arouse diagnostic suspicion [@bb0035], [@bb0040], [@bb0045], however, the clinicopathological features of LSAOC remain poorly defined. Here we present the largest case series of LSAOC in known Lynch syndrome mutation carriers. We explore the clinicopathological features of these tumors, associations between the genetics and the disease and disease-specific survival analysis.

2. Methods {#s0010}
==========

The clinical records of the Manchester Centre for Genomic Medicine, a large tertiary referral genetics center in the North West of England in the United Kingdom, were searched for cases of LSAOC. This was facilitated by an electronic prospectively maintained clinical database, which is maintained by a dedicated data manager. All those included on the database have given formal consent to have their data analyzed anonymously and published. The genetic center serves a population of 5.6 million people. In total 1047 proven mutation carriers are included in the database. Of these, 577 are women. Only those with a confirmed diagnosis of Lynch syndrome based on germline sequencing were included in this study. [Fig. 1](#f0005){ref-type="fig"} outlines the numbers of patients included and excluded at each stage of stratification. Patients at potential risk of LS are referred as either affected or unaffected individuals where there is young onset of colorectal, endometrial and/or ovarian cancer or a pattern of these cancers suggestive of LS. Testing is usually directed by immunohistochemistry (IHC) of relevant tumors with initial testing by next generation sequencing of *MSH2*, *MLH1* and *MSH6*. *PMS2* is only tested if there is loss of PMS2 protein on IHC. All mutations are assessed for pathogenicity utilizing the INSiGHT dataset. All Lynch syndrome diagnostic tests are performed within a nationally accredited genetics laboratory and with full consent from patients.

Women with known Lynch syndrome and those considered at risk of LS or an LS-like syndrome are offered gynecological cancer surveillance even in the absence of a proven MMR mutation. This has been routine practice since 1997. Each year, women undergo an outpatient hysteroscopy and transvaginal ultrasound surveillance for endometrial pathology. Ovarian surveillance by ultrasound and serum cancer antigen 125 (CA125) testing is individualized according to family history. There are currently 87 women enrolled in this surveillance program, approximately two thirds of whom have not yet had their Lynch syndrome status tested or confirmed.

We collated clinical data from the database and the patients\' case notes for all women with proven LSAOC. Pedigree data were used to assess whether they met the Bethesda guideline criteria. Patients were tracked from the time of LSAOC diagnosis and censored at the time of death or last follow up. Individual date of death data were collected from the National Cancer Registry during the course of the patient\'s clinical care. In addition, cause of death was established from official death certificates, where appropriate. Pathology reports were collected and cancers were staged, on the basis of these original reports, in line with the International Federation of Gynecology and Obstetrics (FIGO) 2009 criteria. This allowed for standardization of the disease picture. All data were anonymized the time of data extraction.

Descriptive statistics were generated, including means, confidence intervals and proportions. Statistical analysis was performed using a combination of both Graphpad Prism version 7 (California USA) and StataSE version 13 (StataCorp Texas USA) software. Statistical hypothesis testing was completed with the use of analysis of variance or student *t*-test, as appropriate. Results were tabulated or presented graphically. Percentage survival was generated with the use of Kaplan-Meier algorithm.

3. Results {#s0015}
==========

In our cohort, the lifetime cumulative risk of LSAOC was 2% at 40 years of age, 15% at 60 years and 20% at 80 years of age ([Fig. 2](#f0010){ref-type="fig"}). Twenty-four percent of women were censored from analysis at the time of bilateral salpingo-oophorectomy for LSAEC prevention or treatment. In total, 53 LSAOC tumors were identified. The mean age of diagnosis was 51 years (range 24--70 years). Diagnosis of OC dated from 1956 to 2015. Mean period of follow up, from the time of LSAOC diagnosis, was 64 months. Three of the four Lynch syndrome genes were represented in the population with the exception of *PMS2*. One individual carried a bi-allelic mutation in *PMS2* giving her a diagnosis of constitutional mismatch repair deficiency (CMMRD) rather than Lynch syndrome, and was excluded from analysis. In total, there were 17 *MLH1*, 28 *MSH2* and 7 *MSH6* proven mutation carriers. The mean age of LSAOC in *MLH1* was 48 years, in *MSH2* it was 52 years and in *MSH6* the average was 53 years. There was no significant difference between age at diagnosis of LSAOC and mutated gene (*p* = 0.51 ANOVA), although numbers are small. Of the 36 women with complete datasets ([Table 1](#t0005){ref-type="table"}), eight met the Bethesda criteria for diagnosis of Lynch syndrome; this constitutes just 22% of the cohort.

The histopathological features of the LSAOC tumors are presented in [Table 2](#t0010){ref-type="table"}. There was a preponderance of high-grade endometrioid tumors (*n* = 19), with them constituting 53%. This was followed high-grade serous adenocarcinomas (*n* = 6), and mixed tumors (*n* = 4) constituting 17% and 11% respectively. Clear cell carcinoma (*n* = 4) constituted 11%. There were singular recorded cases of anaplastic neuroendocrine (*n* = 1), yolk sac (*n* = 1) and carcinosarcoma (*n* = 1) tumors, each constituting 3%. The stage of the disease was verified in 35 cases. Most patients presented with stage 1 disease \[stage 1a, 12 (34%); stage 1b, 4 (11%); stage 1c, 7 (20%)\]. Seven women (20%) presented with stage 2 disease, 4 (11%) with stage 3 and 1 (3%) with stage 4 disease, respectively.

Synchronous endometrial cancer or atypical hyperplasia was seen in 9 women (25%). Contemporaneous histological opinion favored synchronous primary ovarian pathology rather than metastasis. There were 11 deaths (29%) recorded within the cohort. Of these, six (17%) had OC documented as the primary cause of death. Three of the six were stage 1, and the remaining three were documented as stage 2, 4 and unknown, respectively. None of these cases underwent a formal post-mortem. LSAOC specific survival analysis indicates overall survival around 80% at 2 years. This is shown in [Fig. 3](#f0015){ref-type="fig"}. Advanced stage disease was associated with poorer prognosis ([Fig. 4](#f0020){ref-type="fig"}). This did not reach significance (*p* = 0.11 student *t*-test), however there were very few women in the advanced disease cohort.

All MMR mutated women were offered gynecological malignancy surveillance from 1998. The mean duration of surveillance was 50 months. Of our cohort of LSAOC, five women had undergone regular annual surveillance for gynecological malignancies. Two LSAOC were detected through the gynecological cancer surveillance program. Both were found on transvaginal ultrasound and subsequently identified as FIGO 2009 1c endometrioid ovarian cancer and 1c clear cell ovarian carcinoma aged 33 and 34 years respectively; both remain alive without recurrence 12 and 11 years post diagnosis. Three other women presented with incidental LSAOC at the time of surgery for screen-detected stage 1a endometrial cancer (*n* = 2) or atypical endometrial hyperplasia (*n* = 1). Two of these women had occult, microscopic stage 1a or 1b OC; the third had stage 2 disease. The latter patient\'s ovarian tumor was not visualized on ultrasound scan during uterine surveillance, but she had an elevated serum CA125 level. All five women with LSAOC who had been under gynecological surveillance are alive and well. The majority of other LSAOC women were diagnosed with Lynch syndrome after their OC diagnosis (*n* = 41).

4. Discussion {#s0020}
=============

Here we present the largest single institution cohort study of ovarian cancer in proven Lynch syndrome carriers and the first from the United Kingdom. We add to the body of evidence that LSAOC presents at an earlier age than OC in non-Lynch syndrome carriers. The lifetime cumulative risk of OC in our cohort was 20%. It is likely that this is an overestimate as we have not corrected for testing bias, whereby affected family members are more likely to be tested for LS. In order to adjust for this, analyses need to take into account untested first-degree relatives who may still have up to a 50% chance of carrying the mutation. Our previous work accounting for this estimated cumulative lifetime risk of OC to be closer to 6--8% [@bb0050]. Here, we show that LSAOC generally presents at an early stage, in keeping with previous reports [@bb0050], [@bb0055]. The most common histological subtype in our cohort was endometrioid adenocarcinoma but high-grade serous tumors were also seen.

Previous work suggests that the lifetime risk of OC in Lynch syndrome is around 6--14% [@bb0060] depending on the particular gene that is mutated. A 20% lifetime risk of OC for *MLH1,* 24% *MSH2* and a 1% risk for *MSH6* mutation was reported in one large series of carriers from 537 families [@bb0020]. In our cohort, similar proportions of women with *MLH1*, *MSH2* and *MSH6* mutations developed OC ([Fig. 1](#f0005){ref-type="fig"}), however only one woman with a *PMS2* mutation developed OC. She had a bi-allelic *PMS2* mutation and thus a diagnosis of constitutional mismatch repair deficiency (CMMRD) rather than Lynch syndrome. There were no cases of OC amongst our 21 heterozygous *PMS2* mutation carriers.

This study adds to the substantial evidence reporting an earlier age of onset of LSAOC compared to sporadic OC [@bb0050], [@bb0065], [@bb0070], [@bb0075]. The median age was 48 years and 79% of women in our cohort were under the age of 50 when they were diagnosed with OC. This compares to a median age of 63 years in the general population [@bb0080]. Our data highlight the importance of a low threshold for Lynch syndrome diagnostic testing alongside BRCA testing in women who present with OC under the age of 50 years. Established clinical criteria for Lynch testing, specifically the Bethesda guidelines, are not sensitive in the diagnosis of LSAOC, with only 9 women meeting the criteria.

Historically, ovarian cancer has been categorized based on morphology into Type I and Type II disease [@bb0080], although modern genetic approaches call into question the utility of such an approach, favoring genetic categorization based on mutation status as it better predicts prognosis and treatment response [@bb0080], [@bb0085], [@bb0090]. Indeed there is evidence that LSAOC is genetically distinct from sporadic OC [@bb0095]. Nonetheless, Type I disease is typically low grade with an improved overall survival rate compared with high grade, type II disease [@bb0080], [@bb0090]. We found a predominance of Type I tumors in our cohort, with over 50% of endometrioid morphology. This may help to explain the good survival rates in our population. In non-Lynch syndrome and BRCA-associated OC, high-grade serous cancers predominate [@bb0085]. We found a smaller proportion of high-grade serous OC in our cohort, similar to the results of Helder-Woolderink et al. [@bb0045]. Their systematic review draws its histological projections from studies where subjects were not proven Lynch syndrome carriers, in contrast to the current study [@bb0075]. The 10-year overall survival of LSAOC was 75% in our cohort. This compares with a 10-year survival of 35% for non-Lynch syndrome associated OC [@bb0095]. Most of the LSAOC in our cohort (65%) presented at FIGO stage 1 with relatively few (17%) OC-related deaths. Deaths attributed to OC occurred in women with endometrioid, mixed or clear cell tumors, but not high grade serous tumors, all but two of whom (*n* = 4, 66%) had stage 1 disease at presentation.

Strengths of our study include the large number of individuals in our dataset (*n* = 1047), all with documented germline mutations in one of their MMR genes. A dedicated data manager prospectively maintains our database to ensure its accuracy and completeness. It forms the basis by which clinical follow-up is organized and is regularly audited for quality assurance. Cause of death is confirmed through vertical sources including the National Cancer Registry and through death certification. This ensures the robustness of our survival analyses. Our study is limited by small numbers because LSAOC is rare. The accuracy of the cause of death data is uncertain since it is based on expert opinion in death certification rather than post-mortem findings. We also have limited events for our survival analysis; this is especially true of deaths in advanced staged disease, mainly because most women presented early. Our work needs validation through international collaboration. Our survival data are comparable with the largest cohort described in the literature [@bb0050]. However, only prospective studies can fully investigate the impact of stage, early detection and treatment modality on survival from LSAOC.

OC prevention and early detection may improve disease specific outcomes in the general population and BRCA mutation carriers [@bb0085], [@bb0090], [@bb0095]. The evidence for such an impact in LSAOC is poorly established. There is general consensus that women with Lynch syndrome should be offered risk-reducing prophylactic hysterectomy and bilateral salpingo-oophorectomy at around 45 years of age [@bb0100], [@bb0105], [@bb0110]. The utility of OC surveillance in Lynch syndrome is not yet evidence based [@bb0115]. Nonetheless, we are encouraged by the results in our cohort with two of five OC\'s detected at stage 1 through our local surveillance program, and another three with occult disease diagnosed at hysterectomy for screen-detected endometrial abnormalities. Surveillance can be tailored to individual women since *MSH6* carriers have a high risk of endometrial cancer but a lower risk of OC [@bb0070], [@bb0120]. Women with *PMS2* mutations appear to be at lowest risk of OC. Large collaborative retrospective studies, or adequately powered prospective studies, are needed to provide new insights into LSAOC.
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![A flow diagram outlining the inclusion stratification for the study. Asterix (\*) denotes patient with homozygous *PMS2* mutation, excluded from further analysis.](gr1){#f0005}

![Lifetime cumulative incidence of ovarian cancer in our cohort (*n* = 577). Those who had undergone bilateral oophorectomy (*n* = 140) were censored at the date of oophorectomy.](gr2){#f0010}

![Overall survival for women diagnosed with Lynch syndrome associated ovarian cancer in our cohort.](gr3){#f0015}

![Survival in LSAOC stratified by FIGO 2009 stage.](gr4){#f0020}

###### 

Tabulated clinical information regarding LSAOC and subsequent cancer diagnoses. Only cases with near complete data sets are shown. *Abbreviations*: NK: not known, CRC: colorectal cancer, AH: atypical hyperplasia, AC: adjuvant chemotherapy, EC: endometrial cancer, TCC: transitional cell carcinoma, RCC, renal cell carcinoma, DCIS: ductal carcinoma in situ. \*signifies woman whose AH or EC was detected during gynecological surveillance and who was found to have a synchronous OC following hysterectomy and removal of both ovaries; \*\* signifies concurrent cancer diagnosis at time of LSAOC diagnosis. \#signifies cause of death was attributed to OC. § is a patient with bi-allelic PMS2 mutation and therefore constitutional mismatch repair deficiency (CMMRD) rather than LS and is included here for information only.

Table 1

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ID    Mutation              Tumor               Age at diagnosis   Year of diagnosis   Screen detected   FIGO (2009)   Treatment       Outcome          Other Neoplasms
  ----- --------------------- ------------------- ------------------ ------------------- ----------------- ------------- --------------- ---------------- -----------------------------------
  1     *MLH1*                Endometriod         42                 2006                No                1b            Surgery         Alive            Nil

  2     *MLH1*                Mixed               52                 1997                No                2a            Surgery         Dead (1997)      Nil

  3     *MLH1*                Clear cell          47                 2004                No                1a            Surgery         Dead \# (2006)   Nil

  4     *MLH1*                Endometrioid        38                 2012                No\*              2c            Surgery         Alive            Dukes A CRC and AH\*\*

  5     *MLH1*                Endometrioid        37                 1997                No                1b            Surgery + AC    Alive            Nil

  6     *MLH1*                Clear cell          60                 2005                No                2b            Surgery + AC    Alive            Nil

  7     *MLH1*                Endometrioid        45                 1960                No                1a            Surgery         Dead (1996)      EC\*\*

  8     *MLH1*                Endometrioid        46                 1988                No                3a            Surgery         Dead \# (1989)   EC\*\*

  9     *MSH2*                Endometrioid        24                 1956                No                1a            Surgery         Alive            Breast (1991 &2006)\
                                                                                                                                                          Ureteric (1986)\
                                                                                                                                                          Skin (numerous)\
                                                                                                                                                          EC (1965)

  10    *MSH2*                High grade serous   47                 2003                No                1c            Surgery         Alive            EC\*\*

  11    *MSH2*                Mixed               33                 2011                No                3c            Surgery + AC    Alive            Nil

  12    *MSH2*                High grade serous   34                 1973                No                2a            NK              Dead (1991)      Nil

  13    *MSH2*                Endometrioid        41                 2008                No\*              1a            Surgery (?AC)   Alive            EC\*\*\
                                                                                                                                                          Brenner tumor (benign) left ovary

  14    *MSH2*                Other               48                 2005                No                1a            Surgery + AC    Alive            Nil

  15    *MSH2*                Clear cell          34                 2005                Yes               1c            Surgery         Alive            Caecum Dukes CRC 32\
                                                                                                                                                          Sigmoid Dukes CRC 34

  16    *MSH2*                Endometrioid        51                 2014                No                1a            Surgery + AC    Alive            Nil

  17    *MSH2*                High grade serous   25                 1988                No                1c            Surgery         Alive            Nil

  18    *MSH2*                Endometrioid        42                 1999                No                1a            Surgery         Dead\#\          Nil
                                                                                                                                         (2000)           

  19    *MSH2*                High grade serous   50                 1999                No                1c            Surgery         Alive            Nil

  20    *MSH2*                Endometrioid        41                 2009                No                1c            Surgery         Alive            Nil

  21    *MSH2*                Endometrioid        41                 2012                No                1b            Surgery         Alive            Nil

  22    *MSH2*                Carcinosarcoma      41                 1994                No                2a            Surgery         Dead (1997)      EC\*\*

  23    *MSH2*                Endometrioid        51                 2005                No                1c            Surgery         Dead\#\          Nil
                                                                                                                                         (2006)           

  24    *MSH2*                High grade serous   70                 2005                No                3b            Surgery + AC    Alive            Dukes C CRC (1982)\
                                                                                                                                                          TCC bladder (2004)\
                                                                                                                                                          RCC (2007)

  25    *MSH2*                Endometrioid        43                 1997                No                1a            Surgery         Alive            DCIS (1989)

  26    *MSH2*                Endometrioid        57                 2011                No                2a            NK              Alive            EC\*\*

  27    *MSH2*                High grade serous   67                 2006                No                1a            Surgery         Alive            TCC (1997)

  28    *MSH2*                Endometrioid        41                 2008                No\*              1b            Surgery         Alive            EC\*\*

  29    *MSH2*                Clear cel           46                 1984                No                NK            Surgery         Dead\#\          Oesophageal (1969)
                                                                                                                                         (1985)           

  30    *MSH2*                Endometrioid        55                 1986                No                3a            Surgery         Dead (2011)      Duke C CRC (1989)

  31    *MSH2*                Endometrioid        33                 2004                Yes               1c            Surgery         Alive            Nil

  32    *MSH6*                Mixed               67                 2012                No                4             Surgery + AC    Dead\# (2015)    Dukes B CRC (2012)

  33    *MSH6*                Other               33                 1971                No                1a            missing data    missing data     missing data

  34    *MSH6*                Endometrioid        46                 1992                No                1a            Surgery         Alive            Nil

  35    *MSH6*                Mixed               49                 2010                No                2a            Surgery + AC    Alive            Nil

  36    *MSH6*                Endometrioid        44                 2001                No                1b            Surgery + AC    Alive            Benign dermoid cyst right ovary

  37\   *PMS2* (homozygote)   Mixed               27                 2012                No                1c (both)     Surgery         Alive            Gastric Adenocarcinoma\
  §                                                                                                                                                       EC\*\*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Distribution of histopathology by Lynch syndrome gene mutation.

Table 2

  Histological type                        Number   Mutation type   Number
  ---------------------------------------- -------- --------------- --------
  Endometrioid                             19       *MLH1*          5
  *MSH2*                                   12                       
  *MSH6*                                   2                        
  Clear cell                               4        *MLH1*          2
  *MSH2*                                   2                        
  *MSH6*                                   0                        
  High grade serous                        6        *MLH1*          0
  *MSH2*                                   6                        
  *MSH6*                                   0                        
  Carcinosarcoma                           1        *MLH1*          0
  *MSH2*                                   1                        
  *MSH6*                                   0                        
  Mixed                                    4        *MLH1*          1
  *MSH2*                                   1                        
  *MSH6*                                   2                        
  Other[a](#tf0005){ref-type="table-fn"}   2        *MLH1*          0
  *MSH2*                                   1                        
  *MSH6*                                   1                        

In the other category 1 × Yolk sac (*MSH6*) and 1 × Anaplastic neuroendocrine (*MSH2*).
